Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare ...

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2018 10

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2018 10

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2018 12

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2018 13

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2018 14

2.4.1 AbbVie Raises USD6 Billion in Public Offering of Notes 14

2.4.2 Pfizer Raises USD4 Billion in Public Offering of Notes 14

2.4.3 Abbott Labs Raises USD4 Billion in Public Offering of Bonds 15

2.4.4 Affimed to Enter into Co-Development Agreement with Genentech 15

2.4.5 Consortium of Investors to Acquire Remaining Shares in China Biologic Products for USD3.9 Billion 15

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2018 17

3.1.1 Top M&A Deals in Q3 2018 18

3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2017 - Q3 2018 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2018 20

3.2.1 Top Initial Public Offerings in Q3 2018 21

3.2.2 Top Secondary Offerings in Q3 2018 21

3.2.3 Top PIPE Deals in Q3 2018 22

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2017 – Q3 2018 23

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2018 24

3.3.1 Top Venture Financing Deals in Q3 2018 25

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2018 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2018 26

3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2017 - Q3 2018 27

3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2017 – Q3 2018 28

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2017 – Q3 2018 29

3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2018 30

3.5.1 Top Private Equity Deals in Q3 2018 31

3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2017 - Q3 2018 32

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2018 33

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2018 33

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2017 - Q3 2018 34

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 35

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2018 36

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2018 36

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2018 37

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 38

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2017 - Q3 2018 39

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2017 - Q3 2018 40

4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 41

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2018 43

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2018 43

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 44

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2018 45

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2018 45

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2018 46

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2017 - Q3 2018 47

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2017 - Q3 2018 48

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2017 - Q3 2018 49

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2017 - Q3 2018 50

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2017 - Q3 2018 52

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2018 54

6.1.1 Oncology – Deals of the Quarter 55

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2018 58

6.2.1 Central Nervous System – Deals of the Quarter 59

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2018 61

6.3.1 Infectious Disease – Deals of the Quarter 62

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2018 64

6.4.1 Immunology – Deals of the Quarter 65

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2018 67

6.5.1 Metabolic Disorders – Deals of the Quarter 68

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2018 70

6.6.1 Cardiovascular – Deals of the Quarter 71

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2018 73

6.7.1 Gastrointestinal – Deals of the Quarter 74

6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2018 76

6.8.1 Dermatology – Deals of the Quarter 77

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2018 78

6.9.1 Respiratory – Deals of the Quarter 79

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2018 81

6.10.1 Ophthalmology – Deals of the Quarter 82

7 Deal Summary by Geography 84

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2018 84

7.1.1 North America – Deals of the Quarter 85

7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2018 87

7.2.1 Europe – Deals of the Quarter 88

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2018 90

7.3.1 Asia-Pacific – Deals of the Quarter 91

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2018 92

7.4.1 Rest of the World – Deals of the Quarter 93

8 Pharmaceuticals & Healthcare, Global, Top Advisors 94

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2017 - Q3 2018 94

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2017 - Q3 2018 95

9 Further Information 96

9.1 Methodology 96

9.2 About GlobalData 97

9.3 Contact Us 97

9.4 Disclosure information 97

9.5 Disclaimer 98

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 ...

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 11

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2018 13

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2018 14

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 – Q3 2018 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2018 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2017 - Q3 2018 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2018 21

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2018 21

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2018 22

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 23

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 24

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2018 25

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2018 26

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 27

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2017 – Q3 2018 28

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2017 – Q3 2018 29

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 – Q3 2018 30

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2018 31

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 32

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 33

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 34

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 35

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018 36

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2018 36

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2018 37

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 38

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018 40

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 42

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 43

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 44

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2018 45

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2018 45

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2018 46

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 47

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2017 - Q3 2018 48

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018 51

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 53

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 55

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 59

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 62

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 65

Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 68

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 71

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 74

Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 77

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 79

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 82

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 85

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 88

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 91

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 93

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 94

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 95

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 10

Figure ...

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2018 12

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2018 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2017 – Q3 2018 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q3 2017 – Q3 2018 23

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 24

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2018 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2018 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2017 - Q3 2018 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2017 – Q3 2018 28

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2017 – Q3 2018 30

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2017 - Q3 2018 32

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 33

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 38

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018 39

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018 40

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 43

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 44

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 47

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 48

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2017 - Q3 2018 49

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2017 - Q3 2018 50

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018 52

Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 54

Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 58

Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 61

Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 64

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 67

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 70

Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 73

Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 76

Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 78

Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 81

Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 84

Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 87

Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 90

Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 92

Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 94

Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018 95

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

Syndicated reports are detailed with easy referencing, and even the forecast models are detailed with analyst references along with most comprehensive M&A database

  Adamas Pharmaceuticals, Inc.